TD Cowen Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target reduced by stock analysts at TD Cowen from $49.00 to $18.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target points to a potential upside of 21.96% from the stock’s previous close.

RARE has been the topic of a number of other research reports. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating on the stock in a report on Thursday. Guggenheim lowered their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Wells Fargo & Company downgraded Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $50.00 to $18.00 in a report on Thursday. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Finally, Cantor Fitzgerald decreased their price target on shares of Ultragenyx Pharmaceutical from $103.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $40.95.

Ultragenyx Pharmaceutical Stock Down 44.4%

Shares of RARE stock traded down $11.77 during trading hours on Thursday, reaching $14.76. 14,828,400 shares of the stock traded hands, compared to its average volume of 2,313,873. The firm has a market capitalization of $1.46 billion, a PE ratio of -2.54 and a beta of 0.31. Ultragenyx Pharmaceutical has a 1-year low of $13.81 and a 1-year high of $39.89. The business has a fifty day moving average price of $28.36 and a 200 day moving average price of $25.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter last year, the business posted ($1.17) EPS. The company’s revenue was up 28.5% on a year-over-year basis. Research analysts expect that Ultragenyx Pharmaceutical will post -3.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Ultragenyx Pharmaceutical by 14.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after buying an additional 29,984 shares in the last quarter. Creative Planning bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth $454,000. American Century Companies Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $366,000. M&T Bank Corp increased its holdings in Ultragenyx Pharmaceutical by 19.7% in the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 1,192 shares during the period. Finally, Amundi boosted its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 93,189 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial long-term value in Ultragenyx’s commercial portfolio and remaining pipeline. Canaccord Genuity, Cantor Fitzgerald, and HC Wainwright maintained “buy” or “overweight” ratings, with price targets of $37, $33, and $25, respectively. Analyst rating reports
• Positive Sentiment: Wall Street attention is shifting toward Ultragenyx’s established commercial business and potential cost reductions following the trial failure, which could help preserve cash and support operations. Barron’s report on Ultragenyx
• Positive Sentiment: The company recently reported encouraging 96-week data for GENGLYCOS (DTX401) in glycogen storage disease type Ia, including a 61% average reduction in daily cornstarch use while maintaining glycemic control. Ultragenyx GENGLYCOS trial publication
• Neutral Sentiment: Despite the widespread target reductions, some analysts’ revised targets remain above the current trading level, including JPMorgan’s $36 target and Wedbush’s $23 target. However, both firms moved to “neutral,” indicating reduced conviction after the clinical setback. JPMorgan analyst update
• Negative Sentiment: Ultragenyx said the Phase 3 Aspire study of its Angelman syndrome drug did not achieve either the primary endpoint—change in Bayley-4 cognitive score—or the key secondary MDRI endpoint. The failure undermines one of the company’s largest expected growth opportunities. Ultragenyx Aspire Phase 3 results
• Negative Sentiment: Analysts responded with a broad reassessment: Bank of America, William Blair, Wells Fargo, JPMorgan, Evercore, Wedbush, and Baird downgraded or moved to neutral-equivalent ratings. Price targets were cut substantially, including Baird’s reduction from $40 to $16 and Wells Fargo’s from $50 to $18. Baird downgrade report

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.